The effect of HAART on HIV RNA trajectory among treatment-naïve men and women: A segmental bernoulli/lognormal random effects model with left censoring

Epidemiology

Volumn 21, Issue SUPPL. 4, 2010, Pages

  Chu, Haitao ^a   Gange, Stephen J ^b   Li, Xiuhong ^b   Hoover, Donald R ^c   Liu, Chenglong ^d   Chmiel, Joan S ^e   Jacobson, Lisa P ^b  

^a IL   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STATISTICAL MODEL; VIRUS LOAD; CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFECTS; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; TIME; VIROLOGY;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PROSPECTIVE STUDIES; RNA, VIRAL; TIME; VIRAL LOAD;

EID: 77953915821     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/EDE.0b013e3181ce9950     Document Type: Article

References (37)

1. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent anti-retroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA. 1998;280:1497-1503.
2. Palella FJ Jr, Deloria-Knoll M, Chmiel JS, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med. 2003;138:620-626
3. The CASCADE Collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet. 2000;355: 1158-1159.
4. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside Analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.
5. Anastos K, Barron Y, Cohen MH, et al. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med. 2004;140: 256-264.
6. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science. 1997;278:1447-1450.
7. Powderly WG, Saag MS, Chapman S, Yu G, Quart B, Clendeninn NJ. Predictors of optimal virological response to potent antiretroviral therapy. AIDS. 1999;13:1873-1880.
8. Dornadula G, Zhang H, VanUitert B, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA. 1999;282:1627-1632.
9. Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med. 1999;340:1614-1622.
10. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med. 1999;340:1605-1613.
11. Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. JAMA. 2005; 293:817-829.
12. Di Mascio M, Markowitz M, Louie M, et al. Dynamics of intermittent viremia during highly active antiretroviral therapy in patients who initiate therapy during chronic versus acute and early human immunodeficiency virus type 1 infection. J Virol. 2004;78: 10566-10573.
13. Di Mascio M, Ribeiro RM, Markowitz M, Ho DD, Perelson AS. Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy. Math Biosci. 2004;188:47-62.
14. Di Mascio M, Markowitz M, Louie M, et al. Viral blip dynamics during highly active antiretroviral therapy. J Virol. 2003;77:12165-12172. (Pubitemid 37339869)
15. Tarwater PM, Margolick JB, Jin J, et al. Increase and plateau of CD4 T-cell counts in the 3-1/2 years after initiation of potent antiretroviral therapy. J AIDS. 2001;27:168-175.
16. Chu H, Gange SJ, Yamashita TE, et al. Individual variation in CD4 T-cell Trajectory among human immunodeficiency virus-infected men and women on long term highly active antiretroviral therapy: an application using a Bayesian random change point model. Am J Epidemiol. 2005;162:787-797.
17. Gange SJ, Munoz A, Chmiel JS, et al. Identification of inflections in T-cell counts among HIV-1-infected individuals and relationship with progression to clinical AIDS. Proc Natl Acad Sci USA. 1998;95:10848-10853.
18. Li X, Chu H, Gallant JE, et al. Bimodal virologic response to antiretroviral therapy for HIV infection: an application using a mixture model with left censoring. J Epidemiol Commun Health. 2006;60:811-818.
19. Skrondal A, Rabe-Hesketh S. Generalized Latent Variable Modeling: Multilevel, Longitudinal, and Structural Equation Models. 1st ed. Boca Raton, FL: Chapman & Hall/CRC; 2004.
20. Lyles RH, Lyles CM, Taylor DJ. Random regression models for human immunodeficiency virus ribonucleic acid data subject to left censoring and informative drop-outs. J Roy Stat Soc Ser C-Appl Stat. 2000;49:485-497.
21. Thiebaut R, Jacqmin-Gadda H, Babiker A, Commenges D. Joint modelling of bivariate longitudinal data with informative dropout and left-censoring, with application to the evolution of CD4+ cell count and HIV RNA viral load in response to treatment of HIV infection. Stat Med. 2005;24:65-82.
22. Cole SR, Hernan MA, Anastos K, Jamieson BD, Robins JM. Determining the effect of highly active antiretroviral therapy on changes in human immunodeficiency virus type 1 RNA viral load using a marginal structural left-censored mean model. Am J Epidemiol. 2007; 166:219-227.
23. Berk KN, Lachenbruch PA. Repeated measures with zeros. Stat Meth Med Res. 2002;11:303-316.
24. Moulton LH, Halsey NA. A mixture model with detection limits for regression analyses of antibody response to vaccine. Biometrics. 1995; 51:1570-1578.
25. Moulton LH, Curriero FC, Barroso PF. Mixture models for quantitative HIV RNA data. Stat Meth Medl Res. 2002;11:317-325.
26. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR Jr. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol. 1987;126: 310-318.
27. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology. 1998;9:117-125.
28. Yamashita TE, Phair JP, Munoz A, et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS. 2001;15:735-746.
29. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. April 7 2005. Available at: http://aidsinfonihgov/guidelines/. Accessed August 5 2005.
30. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41:1-19.
31. Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York: Springer; 2000.
32. Hughes JP. Mixed effects models with censored data with application to HIV RNA levels. Biometrics. 1999;55:625-629.
33. Chu H, Moulton LH, Mack WJ, Passaro DJ, Barroso PF, Munoz A. Correlating two continuous variables subject to detection limits in the context of mixture distributions. J Roy Stat Soc Ser C. 2005;54:831-845.
34. Lyles RH, Williams JK, Chuachoowong R. Correlating two viral load assays with known detection limits. Biometrics. 2001;57:1238-1244.
35. Chu H, Nie L. A note on comparing exposure data to a regulatory limit in the presence of unexposed and a limit of detection. Biometric J. 2005;47:880-887.
36. Burnham KP, Anderson DR. Model Selection and Inference: A Practical Information-Theoretic Approach. New York: Springer-Verlag; 1998.
37. Halloran ME, Preziosi MP, Chu HT. Estimating vaccine efficacy from secondary attack rates. J Am Stat Assoc. 2003;98:38-46.